Prostate Cell News Volume 3.12 | Mar 30 2012

LABORATORY RESEARCH

Proteomic Analysis of Microvesicles Released by the Human Prostate Cancer Cell Line PC-3
Researchers present the results from a proteomic analysis of microvesicles released to the extracellular environment by the metastatic prostate cancer cell line PC-3. [Mol Cell Proteomics] Abstract

RhoA as a Mediator of Clinically Relevant Androgen Action in Prostate Cancer Cells
Researchers show that the small GTPase ras homolog family member A (RhoA) mediates androgen-responsiveness of more than half of serum response factor target genes. [Mol Endocrinol] Abstract

Anticancer Activities of Genistein-Topotecan Combination in Prostate Cancer Cells
Investigators demonstrate the potential anticancer efficacy of genistein-topotecan combination in LNCaP prostate cancer cells and the mechanism of the combination treatment. [J Cell Mol Med] Abstract

Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM
Researchers’ results suggest that the loss of let-7 mediated increased expression of enhancer of zeste homolog 2 (EZH2) contributes to prostate cancer aggressiveness, which could be attenuated by BR-DIM (Bio Response-3,3′-diindolylmethane) treatment, and thus BR-DIM is likely to have clinical impact. [PLoS One] Abstract

Inhibition of mTORC1 Kinase Activates Smads 1 and 5 but Not Smad8 in Human Prostate Cancer Cells, Mediating Cytostatic Response to Rapamycin
Researchers show that rapamycin activates Smads 1 and 5 in human prostate cancer cells and tissues through blocking mTORC1 kinase. [Mol Cancer Res] Abstract

Hedgehog Signaling Inhibition by the Small Molecule Smoothened Inhibitor GDC-0449 in the Bone Forming Prostate Cancer Xenograft MDA PCa 118b
Researchers confirm increased Hedgehog signaling in advanced and bone metastatic castrate resistant prostate cancer and examine the pharmacodynamic effect of Smoothened inhibition by the novel reagent GDC-0449 in an experimental prostate cancer model. [Prostate] Abstract

Zoledronic Acid Influences Growth, Migration and Invasive Activity of Prostate Cancer Cells In Vitro
The influence of the bisphosphonate zoledronic acid on prostate cancer growth, adhesion and invasive behavior was investigated. [Prostate Cancer Prostatic Dis] Abstract

CLINICAL RESEARCH

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
A randomized, placebo-controlled study based on preclinical and clinical data that supports the potential role of vascular endothelial growth factor in prostate cancer was performed to evaluate the addition of bevacizumab to standard docetaxel and prednisone therapy in patients with metastatic castration-resistant prostate cancer. [J Clin Oncol] Abstract

Celecoxib Plus Hormone Therapy versus Hormone Therapy Alone for Hormone-Sensitive Prostate Cancer: First Results from the STAMPEDE Multiarm, Multistage, Randomized Controlled Trial
The STAMPEDE trial was designed to assess whether the early additional use of one or two drugs improves survival in men starting first-line, long-term hormone therapy. Here, scientists report the preplanned, second intermediate analysis comparing hormone therapy plus celecoxib with hormone therapy alone. [Lancet Oncol] Abstract

Statin Use as a Moderator of Metformin Effect on Risk for Prostate Cancer Among Type II Diabetic Patients
This study assessed whether the effect of metformin on prostate cancer incidence varied by statin use among type II diabetic patients. [Diabetes Care] Abstract

Writing the Book of Cancer Knowledge
An academic-industry collaboration is releasing the first results from a new and freely available resource that marries deeply detailed cancer genome data with predictors of drug response, information that could lead to refinements in cancer clinical trials and future treatments. [The Eli and Edythe L. Broad Institute]
Press Release

Kapil Dhingra, Former Head of Roche Oncology, Joins Exosome Diagnostics Board of Directors
Exosome Diagnostics announced that Kapil Dhingra has joined the Exosome Diagnostics Board of Directors. [Exosome Diagnostics, Inc.] Press Release

Wellcome Trust to Launch £200 Million Investment Business for Healthcare and Life Sciences
The Board of Governors of the Wellcome Trust approved the creation of a new business that will invest in emerging businesses and technologies in the healthcare and life sciences sectors. [Wellcome Trust]
Press Release

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Hematology (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

PhD Position – Cell Biology/Infection Research (University of Münster)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Fellow (Louisiana State University Health Sciences Center) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.